Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers ...

Minnesota Attorney General Keith Ellison announced on Monday that a settlement has been reached Novo Nordisk over the high ...

Finally, some good news for Novo Nordisk (NYSE: NVO) shareholders! Twice in the past two months, the Danish manufacturer of GLP-1 drugs for weight loss and diabetes treatment has reported clinical ...

Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much as 22%. Novo Nordisk said a Phase 1b/2a clinical trial of amycretin ...

Novo Nordisk shares rose sharply Friday after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients lose 22% of their bodyweight in a clinical trial. Shares were 10 ...

--Currently up two consecutive days; up 9.05% over this period --Best two day stretch since the two days ending Aug. 9, 2024, when it rose 11.94% --Up 2.14% month-to-date; on pace for best month ...

In an interview with ESPN’s Pete Thamel, Texas quarterback Quinn Ewers said he doesn’t expect to play college football next year, offering some clarity to rampant speculation over the highest ...

Novo Nordisk is facing serious pressure from a powerful adversary. It still has plenty of leeway to penetrate its target market, for now. Investors should keep a close eye on this company.

With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth ...

Quinn Ewers is passing up on some big bucks to enter the 2025 NFL Draft. The now former Texas quarterback turned down an $8 million NIL offer to transfer to another school to play his final ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight loss versus the anticipated 25%. The stock is down 42% from its June ...

Among business leaders in the meeting were Lars Fruergaard Jorgensen, CEO of Novo Nordisk, which generates more than half of its sales in the United States. Novo, which competes with U.S ...